Damages Amount to $2.1 Billion for Teva Pharmaceuticals

By Admin
Share
Two billion dollars is a hefty price to pay for manufacturing generic copies of a drug patented by a pharmaceutical company in the U.S., but Teva Pharm...

Two billion dollars is a hefty price to pay for manufacturing generic copies of a drug patented by a pharmaceutical company in the U.S., but Teva Pharmaceuticals Industries Ltd. is fighting allegations and may have to foot the bill.

The Israeli company is accused of selling generic copies of Protonix, Pfizer Inc.’s wide selling heartburn medication, before its U.S. patent exclusivity expired in 2011.  To cover potential losses, Teva has already booked a $670 million provision for the third quarter of last year.

On Tuesday an annual report Teva filed with the U.S. Securities and Exchange Commission said it estimates the "ultimate resolution of this matter could result in a loss of up to $1.4 billion in excess of the amount accrued."

A June trial is scheduled to investigate Pfizer’s claim for damages in federal court in New Jersey while Teva is moving forward with plans to challenge the court’s decision upholding the validity of the patent protecting rights to Pfizer’s drug.

Block & Pfizer Develop Pharma Manufacturing System

Zoetis of Pfizer Inc Raises $2.2b in IPO

"We intend to seek full compensation for the damages caused by Teva's and Sun's infringement of the patent" covering Protonix, Pfizer spokesman Christopher Loder said in a statement. "We look forward to fully addressing all arguments in court during the damages trial."

If Teva is forced to pay damages in full, it will constitute one of the largest amounts relating to the release of an “at-risk” generic drug before litigation pertaining the braded drug’s patent was resolved.
 

Share

Featured Articles

NTT & Olympus: World's First Cloud Endoscopy System

NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system

Richter BioLogics' New Biopharmaceutical GMP Facility

Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment

GE HealthCare's Pilot Study Shows Value of Portrait Mobile

A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency

50% of Teens to be Affected by Myopia Globally by 2050

Telehealth & COVID-19

NVIDIA’s AI Insights for Diabetes Prevention with GluFormer

Technology & AI

Novo Nordisk's CagriSema Next Gen Weight-Loss Treatment

Medical Devices & Pharma